Advantages of blood pool contrast agents in MR angiography: A pictorial review

Journal of Medical Imaging and Radiation Oncology

Volumn 56, Issue 2, 2012, Pages 187-191

  Lewis, Mark ^a   Yanny, Sarah ^b   Malcolm, Paul N ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b STOKE MANDEVILLE HOSPITAL   (United Kingdom)

Author keywords

Angiography; Blood pool agent; Contrast; Magnetic resonance imaging; Vascular imaging

Indexed keywords

GADOFOSVESET;

AGED; ARTERIOGRAPHY; ARTERIOVENOUS FISTULA; ARTERIOVENOUS MALFORMATION; BLOOD POOL SCINTISCANNING; CASE REPORT; CONGENITAL BLOOD VESSEL MALFORMATION; CONTRAST ENHANCEMENT; FIRST PASS EFFECT; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; KIDNEY ARTERIOGRAPHY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MINIMALLY INVASIVE PROCEDURE; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW; SCLEROTHERAPY; STEADY STATE; THORAX OUTLET SYNDROME; THROMBOSIS; VEIN OCCLUSION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; ORGANOMETALLIC COMPOUNDS; VASCULAR DISEASES;

EID: 84859789633     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2012.02347.x     Document Type: Review

References (13)

1. Prince MR, Narasimham DL, Stanley JC et al. Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. Radiology 1995; 197: 785-92.
2. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 1997; 32: 741-7. (Pubitemid 28053505)
3. Hartmann M, Wiethoff AJ, Hentrich H-R, Rohrer M. Initial imaging recommendations for Vasovist angiography. Eur Radiol 2006; 16 (Suppl 2): B15-23.
4. Grist TM, Korosec FR, Peters DC et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998; 207: 539-44. (Pubitemid 28259075)
5. Meaney JFM, Goyen M. Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol 2007; 17 (Suppl 2): B2-6.
6. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135: 401-11. (Pubitemid 32845865)
7. Vasbinder GBC, Nelemans PJ, Kessels AGH et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 2004; 141: 674-82; discussion 682.
8. McGregor R, Vymazal J, Martinez-Lopez M et al. A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease. Eur J Radiol 2008; 65: 316-25. (Pubitemid 351179949)
9. Meissner OA, Rieger J, Weber C et al. Critical limb ischemia: hybrid MR angiography compared with DSA. Radiology 2005; 235: 308-18. (Pubitemid 40432268)
10. Nikolaou K, Kramer H, Grosse C et al. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology 2006; 241: 861-72. (Pubitemid 46190554)
11. Pedersen SF, Thrysøe SA, Paaske WP et al. CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. J Cardiovasc Magn Reson 2011; 13: 10.
12. Goyen M, Shamsi K, Schoenberg SO. Vasovist-enhanced MR angiography. Eur Radiol 2006; 16 (Suppl 2): B9-14.
13. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. Invest Radiol 2006; 41: 822-30. (Pubitemid 44566363)